Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris

Authors

  • Katharina Boch
  • Ewan A. Langan
  • Enno Schmidt
  • Detlef Zillikens
  • Ralf J. Ludwig
  • Katja Bieber
  • Christoph M. Hammers Department of Dermatology, University of Lübeck, Ratzeburger Allee 160, DE-23562 Lübeck, Germany

DOI:

https://doi.org/10.2340/actadv.v102.907

Keywords:

Pemphigus, Rituximab, Therapy, Immunosuppression, SARS-CoV2, COVID-19

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, et al. Pemphigus. Nat Rev Dis Primers 2017; 3: 17026.

https://doi.org/10.1038/nrdp.2017.26

Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882-894.

https://doi.org/10.1016/S0140-6736(19)31778-7

Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34: 1900-1913.

https://doi.org/10.1111/jdv.16752

Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017; 389: 2031-2040.

https://doi.org/10.1016/S0140-6736(17)30070-3

Colliou N, Picard D, Caillot F, Calbo S, Le Corre S, Lim A, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med 2013; 5: 175ra30.

https://doi.org/10.1126/scitranslmed.3005166

Thaunat O, Morelon E, Defrance T. Am"B"valent: Anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 2010; 116: 515-521.

https://doi.org/10.1182/blood-2010-01-266668

Schmidt E, Goebeler M, Hertl M, Sárdy M, Sitaru C, Eming R, et al. S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 2015; 13: 713-727.

https://doi.org/10.1111/ddg.12612

Daniel BS, Hertl M, Werth VP, Eming R, Murrell DF. Severity score indexes for blistering diseases. Clin Dermatol 2012; 30: 108-113.

https://doi.org/10.1016/j.clindermatol.2011.03.017

Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. [accessed 2022 Feb 14] Available from: https://www.miltenyibiotec.com/_Resources/Persistent/6d7e0fb8a3eab613958d142051e3c7050eb0c8a9/SP_MC_PB_density_gradient.pdf.

Downloads

Additional Files

Published

2022-03-25

How to Cite

Boch, K., Langan, E. A., Schmidt, E., Zillikens, D., Ludwig, R. J., Bieber, K., & Hammers, C. M. (2022). Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris. Acta Dermato-Venereologica, 102, adv00679. https://doi.org/10.2340/actadv.v102.907

Issue

Vol. 102 (2022)

Section

Short Communication

Categories

License

Copyright (c) 2022 Katharina Boch; Ewan A. Langan; Enno Schmidt, Detlef Zillikens, Ralf J. Ludwig, Katja Bieber, Christoph M. Hammers

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.